Aviragen Therapeutics Inc Share Price Nasdaq
Stocks
US0906941002
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| Market Cap | 118M 103M 97.32M 88.37M 166M 11.34B 166M 1.17B 450M 5.77B 444M 434M 18.55B | P/E 2026 * |
-3.04x | P/E 2027 * | -0.57x |
|---|---|---|---|---|---|
| Enterprise Value | 118M 103M 97.32M 88.37M 166M 11.34B 166M 1.17B 450M 5.77B 444M 434M 18.55B | EV / Sales 2026 * |
1x | EV / Sales 2027 * | 50.3x |
| Free-Float |
98.52% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Aviragen Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Steven Lo
CEO | Chief Executive Officer | 60 | 17/03/2024 |
Sean Tucker
CTO | Chief Tech/Sci/R&D Officer | 59 | 29/02/2024 |
Jeroen Grasman
DFI | Director of Finance/CFO | - | 18/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
David Wheadon
BRD | Director/Board Member | 68 | 20/04/2021 |
William Watson
BRD | Director/Board Member | 76 | 03/08/2022 |
Elaine Heron
BRD | Director/Board Member | 79 | 31/12/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.31% | +5.79% | +47.13% | +99.00% | 70.88B | |
| +0.39% | +2.06% | +39.38% | +78.27% | 62.49B | |
| +0.50% | +7.13% | +33.27% | +16.01% | 26.34B | |
| -3.21% | -7.27% | -17.10% | +356.10% | 26.21B | |
| -2.64% | -0.69% | -0.17% | -13.01% | 24.13B | |
| +0.71% | +8.03% | +25.03% | -12.74% | 20.72B | |
| +2.12% | -5.86% | +161.58% | +329.34% | 15.36B | |
| -0.22% | +3.99% | +45.54% | +172.46% | 14.46B | |
| +0.73% | +1.71% | -5.51% | +849.47% | 14.24B | |
| Average | -0.21% | +1.74% | +36.57% | +208.32% | 30.54B | |
| Weighted average by Cap. | -0.28% | +1.49% | +35.68% | +148.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 119M 103M 97.65M 88.67M 166M 11.38B 167M 1.17B 451M 5.79B 446M 436M 18.62B | 2.35M 2.05M 1.93M 1.76M 3.29M 225M 3.31M 23.18M 8.94M 115M 8.83M 8.63M 369M |
| Net income | -47.2M -41.16M -38.86M -35.29M -66.12M -4.53B -66.4M -466M -180M -2.3B -177M -173M -7.41B | -222M -193M -182M -166M -310M -21.26B -312M -2.19B -843M -10.81B -832M -814M -34.78B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
